| abstract |
The invention relates to a genetically modified T lymphocyte and a pharmaceutical composition using it. The T cell has an endogenous T cell receptor (TCR) which is inactivated or inactive, includes the coding of an exogenous receptor capable of binding to a target antigen, and contains an open reading frame regulated by the exogenous receptor. When the exogenous receptor binds to the target antigen, expression of the open reading frame can be initiated. The T lymphocyte has a destructive effect on tumor cells and has reduced side effects and improved safety. |